Further to this it has been shown that supplementation of deoxythymidine and deoxycytidine monophosphates (dTMP + dCMP) in a murine MDS model with a Tk2 H126N (Tk2−/−) knock-in mutation, also showed tissue-specific increases in mtDNA copy number, disease onset delay as well as significantly prolonging the animals’ life span, suggesting bypassing the defective enzyme is an effective therapeutic approach (19). Here, TK2 is linked to myelodysplastic syndrome.